189 related articles for article (PubMed ID: 29698864)
21. Cost-effectiveness analysis of human papillomavirus vaccines for the prevention of cervical cancer in India.
Arora S; Tuffaha H
Asia Pac J Clin Oncol; 2024 Feb; 20(1):55-62. PubMed ID: 37132538
[TBL] [Abstract][Full Text] [Related]
22. A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.
Hutubessy R; Levin A; Wang S; Morgan W; Ally M; John T; Broutet N
BMC Med; 2012 Nov; 10():136. PubMed ID: 23146319
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
Lee VJ; Tay SK; Teoh YL; Tok MY
BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of quadrivalent and nonavalent human papillomavirus vaccines in Ethiopia.
Wondimu A; Postma MJ; van Hulst M
Vaccine; 2022 Mar; 40(14):2161-2167. PubMed ID: 35248423
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
Jit M; Brisson M; Portnoy A; Hutubessy R
Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
[TBL] [Abstract][Full Text] [Related]
26. Costs of delivering human papillomavirus vaccination to schoolgirls in Mwanza Region, Tanzania.
Quentin W; Terris-Prestholt F; Changalucha J; Soteli S; Edmunds WJ; Hutubessy R; Ross DA; Kapiga S; Hayes R; Watson-Jones D
BMC Med; 2012 Nov; 10():137. PubMed ID: 23148516
[TBL] [Abstract][Full Text] [Related]
27. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.
Kiatpongsan S; Kim JJ
PLoS One; 2014; 9(9):e106836. PubMed ID: 25198104
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence.
Li X; Stander MP; Van Kriekinge G; Demarteau N
BMC Infect Dis; 2015 Dec; 15():566. PubMed ID: 26652918
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of human papillomavirus vaccination for adolescent girls in Punjab state: Implications for India's universal immunization program.
Prinja S; Bahuguna P; Faujdar DS; Jyani G; Srinivasan R; Ghoshal S; Suri V; Singh MP; Kumar R
Cancer; 2017 Sep; 123(17):3253-3260. PubMed ID: 28472550
[TBL] [Abstract][Full Text] [Related]
30. The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana.
Vodicka E; Nonvignon J; Antwi-Agyei KO; Bawa J; Clark A; Pecenka C; LaMontagne DS
Vaccine; 2022 Mar; 40 Suppl 1():A85-A93. PubMed ID: 34303563
[TBL] [Abstract][Full Text] [Related]
31. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
32. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
33. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
[TBL] [Abstract][Full Text] [Related]
34. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of sex-neutral HPV-vaccination in Sweden, accounting for herd-immunity and sexual behaviour.
Wolff E; Elfström KM; Haugen Cange H; Larsson S; Englund H; Sparén P; Roth A
Vaccine; 2018 Aug; 36(34):5160-5165. PubMed ID: 30017146
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia.
Aponte-González J; Fajardo-Bernal L; Diaz J; Eslava-Schmalbach J; Gamboa O; Hay JW
PLoS One; 2013; 8(11):e80639. PubMed ID: 24260441
[TBL] [Abstract][Full Text] [Related]
37. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
38. Cervical cancer prevention in Indonesia: An updated clinical impact, cost-effectiveness and budget impact analysis.
Setiawan D; Andrijono ; Hadinegoro SR; Meyta H; Sitohang RV; Tandy G; Perwitasari DA; Postma MJ
PLoS One; 2020; 15(3):e0230359. PubMed ID: 32203527
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of HPV vaccination regime: comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia.
Aljunid S; Maimaiti N; Nur AM; Noor MRM; Wan Puteh SE
BMC Public Health; 2016 Jan; 16():71. PubMed ID: 26803814
[TBL] [Abstract][Full Text] [Related]
40. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study.
Van Minh H; My NTT; Jit M
BMC Health Serv Res; 2017 May; 17(1):353. PubMed ID: 28506297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
